{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011615","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2024-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.067320+00:00","generated_at":"2026-06-04T05:57:13.284702+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Daré Bioscience reports FY2023 net loss $30.1M, cash $10.5M; XACIATO launched, Ovaprene Phase 3 recruiting","bullets":["Net loss of $30.1M for FY2023; revenue of $2.8M from XACIATO milestone payments.","Cash and equivalents $10.5M at Dec 31, 2023; received $4.7M in grant funding and $17M in offerings/financing.","XACIATO launched in U.S. via Organon; Daré eligible for double-digit royalties and up to $180M milestones.","Ovaprene Phase 3 pivotal study recruiting at 17 U.S. sites; non-hormonal monthly contraceptive candidate.","Sildenafil Cream completed Phase 2b; FDA feedback on Phase 3 design expected in Q2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011615","json":"https://secwatch.observer/filing/0001493152-24-011615.json","markdown":"https://secwatch.observer/filing/0001493152-24-011615.md","text":"https://secwatch.observer/filing/0001493152-24-011615.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224011615/0001493152-24-011615-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224011615/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:57:13.284702+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"68acbdca4f307cbaaa31375badfe0abe6561012d","claim":"Dare Bioscience, Inc. reported financial results for the fiscal year ended December 31, 2023.","evidence_excerpt":"On March 28, 2024, Daré Bioscience, Inc. (the “Company”), issued a press release announcing its financial results for the fiscal year ended December 31, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000149315224011615/0001493152-24-011615-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}